Neurological adverse events associated with anti-tumor necrosis factor alpha treatment

Journal of Neurology

Volumn 257, Issue 9, 2010, Pages 1421-1431

  Tristano, Antonio G ^a  

^a Centro Medico Carpetana   (Spain)

Author keywords

Adalimumab; Anti TNF ; Demyelinating disease; Etanercept; Infliximab; Neurological adverse events; Tumor necrosis factor alpha (TNF )

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHYLPREDNISOLONE; PROTEIN P55; PROTEIN P60; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR 1; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ATAXIA; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CROHN DISEASE; DEMYELINATING DISEASE; DEMYELINATING NEUROPATHY; DRUG MECHANISM; DYSARTHRIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NERVE CELL PLASTICITY; NEUROLOGIC DISEASE; OPTIC NEURITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SENSORY NEUROPATHY; SPINAL CORD DISEASE;

ANIMALS; HUMANS; NERVOUS SYSTEM DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957366385     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-010-5591-7     Document Type: Review

References (101)

1. G Kollias E Douni G Kassiotis D Kontoyiannis 1999 The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease Ann Rheum Dis 58 Suppl. 1 I32 I39 10.1136/ard.58.2008.i32 10577971
2. JP Stubgen 2008 Tumor necrosis factor-α antagonists and neuropathy Muscle Nerve 37 282 292 10.1002/mus.20924 (Pubitemid 351304787)
3. A Cope R Ettinger H McDevitt 1997 The role of TNF-α and related cytokines in the development and function of the autoreactive T-cell repertoire Res Immunol 148 307 312 10.1016/S0923-2494(97)87239-2 9352594 (Pubitemid 27435914)
4. G Kollias E Douni G Kassiotis D Kontoyiannis 1999 The role of tumor necrosis factor and receptors in models of multi organ inflammation, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease Ann Rheum Dis 58 suppl 1 32 39 10.1136/ard.58.2008.i32
5. WH Robinson MC Genovese LW Moreland 2001 Demyelinating and neurologic events reported in association with tumor necrosis factor α antagonism Arthritis Rheum 44 1977 1983 10.1002/1529-0131(200109)44:9<1977::AID- ART345>3.0.CO;2-6 11592357 (Pubitemid 33644038)
6. R Hohlfeld 1996 Inhibitors of tumor necrosis factor-alpha: promising agents for the treatment of multiple sclerosis? Mult Scler 1 376 378 9345421
7. L Zheng G Fisher RE Miller J Peschon DH Lynch MJ Lenardo 1995 Induction of apoptosis in mature T cells by tumour necrosis factor Nature 377 348 351 10.1038/377348a0 7566090
8. A Alldred 2001 Etanercept in rheumatoid arthritis Expert Opin Pharmacother 1 1137 1148 10.1517/14656566.2.7.1137 (Pubitemid 32633716)
9. Enbrel (etanercept) (2007) Current prescribing information. In: Physicians' desk reference. Thompson, Montvale, pp 584-591
10. Humira (adalimumab) (2007) Current prescribing information. In: Physicians' desk reference. Thompson, Montvale, pp 466-471
11. Remicade (infliximab) (2007) Current prescribing information. In: Physicians' desk reference. Thompson, Montvale, pp 971-979
12. M Ramos-Casals Roberto-Perez-Alvarez C Diaz-Lagares MJ Cuadrado MA Khamashta, et al. 2010 Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 9 3 188 193 10.1016/j.autrev.2009.10.003 19854301
13. DA Wetter MD Davis 2009 Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic Mayo Clin Proc 84 11 979 984 10.4065/84.11.979 19880688
14. J Borrás-Blasco A Navarro-Ruiz C Borrás E Casterá 2009 Adverse cutaneous reactions induced by TNF-alpha antagonist therapy South Med J 102 11 1133 1140 19864977
15. P Ghezzi T Mennini 2001 Tumor necrosis factor and motoneural degeneration: an open problem Neuroimmunomodulation 9 4 178 182 10.1159/000049024 11847479 (Pubitemid 34195775)
16. AP Cope RS Liblau XD Yang M Congia C Laudanna RD Schreiber 1997 Chronic tumor necrosis factor alter T cell responses by attenuating T cell receptor signaling J Exp Med 185 1573 1584 10.1084/jem.185.9.1573 9151895 (Pubitemid 27203254)
17. Aggarwal BB, Samanta A, Feldmann M (2000) TNFα. In: Oppenheim JJaFM (ed) Cytokine Reference. Academic Press, London, pp 414-434
18. HT Idriss J Naismith 2000 TNF alpha and the TNF receptor superfamily: structure-function relationship(s) Microsc Res Tech 50 184 195 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H 10891884 (Pubitemid 30610095)
19. DJ MacEwan 2002 TNF receptor subtype signalling: differences and cellular consequences Cell Signal 14 477 492 10.1016/S0898-6568(01)00262-5 11897488 (Pubitemid 34230583)
20. MK McCoy MG Tansey 2008 TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease J Neuroinflammation 5 45 10.1186/1742-2094-5-45 18925972
21. RA Black CT Rauch CJ Kozlosky JJ Peschon JL Slack MF Wolfson, et al. 1997 A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells Nature 385 729 733 10.1038/385729a0 9034190 (Pubitemid 27098094)
22. AP Lieberman PM Pitha HS Shin ML Shin 1989 Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus Proc Natl Acad Sci USA 86 6348 6352 10.1073/pnas.86.16.6348 2474832
23. MC Morganti-Kossman PM Lenzlinger V Hans P Stahel E Csuka E Ammann, et al. 1997 Production of cytokines following brain injury: beneficial and deleterious for the damaged tissue Mol Psychiatry 2 133 136 10.1038/sj.mp. 4000227 9106236
24. CY Chung H Seo KC Sonntag A Brooks L Lin O Isacson 2005 Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection Hum Mol Genet 14 1709 1725 10.1093/hmg/ddi178 15888489 (Pubitemid 41418045)
25. A Creange JP Lefaucheur FJ Authier RK Gherardi 1998 Cytokines and peripheral neuropathies Rev Neurol 154 208 216 9773044
26. N Oka I Akiguchi T Kawasaki K Mizutani H Satoi J Kimura 1998 Tumor necrosis factor-alpha in peripheral nerve lesions Acta Neuropathol 95 57 62 10.1007/s004010050765 9452822 (Pubitemid 28075927)
27. M Grell H Wajant G Zimmermann P Scheurich 1998 The type 1 receptor (CD1 20a) is the high-affinity receptor for soluble tumor necrosis factor Proc Natl Acad Sci USA 95 570 575 10.1073/pnas.95.2.570 9435233 (Pubitemid 28083784)
28. M Grell 1995 Tumor necrosis factor (TNF) receptors in cellular signaling of soluble and membrane-expressed TNF J Inflamm 47 8 17 8913925
29. F Balkwill 2009 Tumor necrosis factor and cancer Nat Rev Cancer 9 5 361 371 10.1038/nrc2628 19343034
30. R Ihnatko M Kubes 2007 TNF signaling: early events and phosphorylation Gen Physiol Biophys 26 3 159 167 18063842
31. E Haas M Grell H Wajant P Scheurich 1999 Continuous autotropic signaling by membrane expressed tumor necrosis factor J Biol Chem 274 25 18107 18112 10.1074/jbc.274.25.18107 10364265 (Pubitemid 29283342)
32. T Weiss M Grell B Hessabi S Bourteele G Müller P Scheurich, et al. 1997 Enhancement of TNF receptor p60-mediated cytotoxicity by TNF receptor p80: requirement of the TNF receptor-associated factor-2 binding site J Immunol 158 5 2398 2404 9036990
33. MH Holtmann MF Neurath 2004 Differential TNF-signaling in chronic inflammatory disorders Curr Mol Med 4 4 439 444 10.2174/1566524043360636 15354874 (Pubitemid 38787012)
34. E Pocsik E Duda D Wallach 1995 Phosphorylation of the 26 kDa TNF precursor in monocytic cells and in transfected HeLa cells J Inflamm 45 152 160 8597870
35. AD Watts NH Hunt Y Wanigasekara G Bloomfield D Wallach BD Roufogalis, et al. 1999 A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling' EMBO J 18 2119 2126 10.1093/emboj/18.8.2119 10205166
36. S Kirchner S Boldt W Kolch S Haffner S Kazak P Janosch, et al. 2004 LPS resistance in monocytic cells caused by reverse signaling through transmembrane TNF (mTNF) is mediated by the MAPK/ERK pathway J Leukoc Biol 75 324 331 10.1189/jlb.0703343 14612430 (Pubitemid 38174590)
37. Tansey MG, Wyss-Coray T (2008) Cytokines in CNS inflammation and disease. In: Lane TE, Carson M (eds) Central nervous system diseases and inflammation. Springer, Berlin
38. KW Selmaj M Farooq WT Norton CS Raine CF Brosnan 1990 Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor J Immunol 144 129 135 2104886
39. JE Merrill 1991 Effects of interleukin-1 and tumor necrosis factoralpha on astrocytes, microglia, oligodendrocytes, and glial precursors in vitro Dev Neurosci 13 130 137 10.1159/000112150 1752215
40. JD Sedgwick DS Riminton JG Cyster H Korner 2001 Tumor necrosis factor: a master-regulator of leukocyte movement Immunol Today 21 110 113 10.1016/S0167-5699(99)01573-X
41. LR Leon 2002 Invited review: cytokine regulation of fever: studies using gene knockout mice J Appl Physiol 92 2648 2655 12015385
42. EC Beattie D Stellwagen W Morishita JC Bresnahan BK Ha M Von Zastrow, et al. 2002 Control of synaptic strength by glial TNFalpha Science 295 2282 2285 10.1126/science.1067859 11910117 (Pubitemid 34258846)
43. M Pickering D Cumiskey JJ O'Connor 2005 Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system Exp Physiol 90 663 670 10.1113/expphysiol.2005.030734 15944202 (Pubitemid 41406053)
44. H Golan T Levav A Mendelsohn M Huleihel 2004 Involvement of tumor necrosis factor alpha in hippocampal development and function Cereb Cortex 14 97 105 10.1093/cercor/bhg108 14654461 (Pubitemid 38018058)
45. JY Zou FT Crews 2005 TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition Brain Res 1034 11 24 10.1016/j.brainres.2004.11.014 15713255 (Pubitemid 40248516)
46. DW Choi 1988 Glutamate neurotoxicity and diseases of the nervous system Neuron 1 623 634 10.1016/0896-6273(88)90162-6 2908446
47. H Hsu J Huang HB Shu V Baichwal DV Goeddel 1996 TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex Immunity 4 387 396 10.1016/S1074-7613(00)80252-6 8612133 (Pubitemid 26174054)
48. A Gross XM Yin K Wang MC Wei J Jockel C Milliman, et al. 1999 Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death J Biol Chem 274 1156 1163 10.1074/jbc.274.2.1156 9873064 (Pubitemid 29058093)
49. JC Goodman CS Robertson RG Grossman RK Narayan 1990 Elevation of tumor necrosis factor in head injury J Neuroimmunol 30 213 217 10.1016/0165-5728(90) 90105-V 2229409
50. FM Hofman DR Hinton K Johnson JE Merrill 1989 Tumor necrosis factor identified in multiple sclerosis brain J Exp Med 170 607 612 10.1084/jem.170.2.607 2754393
51. MK Sharief R Hentges 1991 Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis N Engl J Med 325 467 472 10.1056/NEJM199108153250704 1852181
52. J Beck P Rondot L Catinot E Falcoff H Kirchner J Wietzerbin 1988 Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 78 318 323 10.1111/j.1600-0404.1988.tb03663.x 3146861
53. D Maimone S Gregory BGW Arnason AT Reder 1991 Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis J Neuroimmunol 32 67 74 10.1016/0165-5728(91)90073-G 2002092
54. KW Selmaj CS Raine 1988 Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro Ann Neurol 23 339 346 10.1002/ana.410230405 3132891
55. A Creange L Belec B Clair JC Raphael RK Gherardi 1996 Circulating tumor necrosis factor (TNF)-α and soluble TNF-α receptors in patients with Guillain-Barre syndrome J Neuroimmunol 68 95 99 10.1016/0165-5728(96)00075-6 (Pubitemid 26279251)
56. S Misawa S Kuwabara M Mori N Kawagushi Y Yoshiyama T Hattori 2001 Serum levels of tumor necrosis factor-α in chronic inflammatory polyneuropathy Neurology 56 666 669 11245723
57. MK Sharief B McLean EJ Thompson 1993 Elevated serum levels of tumor necrosis factor-α in Guillain-Barre syndrome Ann Neurol 33 591 596 10.1002/ana.410330606 8498839 (Pubitemid 23161879)
58. F Terenghi S Allaria E Nobile-Orazio 2006 Circulating levels of cytokines and their modulation by intravenous immunoglobulin in multifocal motor neuropathy J Peripher Nerv Syst 11 67 71 10.1111/j.1085-9489.2006.00065.x 16519784 (Pubitemid 43344977)
59. J Zhu E Mix H Link 1998 Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barre syndrome J Neuroimmunol 84 40 52 10.1016/S0165-5728(97)00238-5 9600707 (Pubitemid 28210448)
60. G Said M Hontebeyrie-Joskowicz 1992 Nerve lesions induced by macrophage activation Res Immunol 143 589 599 10.1016/0923-2494(92)80040-R 1455050
61. G Stoll S Jung S Jander P van der Meide HP Hartung 1993 Tumor necrosis factor-alpha in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system J Neuroimmunol 45 175 182 10.1016/0165-5728(93) 90178-2 8331160
62. A Weishaupt W Bruck T Hartung KV Toyka R Gold 2001 Schwann cell apoptosis in experimental autoimmune neuritis of the Lewis rat and the functional role of tumor necrosis factor-α Neurosci Lett 306 77 80 10.1016/S0304-3940(01) 01877-8 11403962 (Pubitemid 32524302)
63. MD Magnano WH Robinson MC Genovese 2004 Demyelination and inhibition of tumor necrosis factor (TNF) Clin Exp Rheumatol 22 suppl. 35 S134 S140 15552527
64. KW Selmaj CS Raine 1995 Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors Neurology 45 S44 S49 7783912
65. BW van Oosten F Barkhof L Truyen JB Boringa FW Bertelsmann BM von Blomberg, et al. 1996 Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal antitumor necrosis factor antibody cA2 Neurology 47 1531 1534 8960740
66. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group 1999 TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study Neurology 53 457 465
67. WE Klinkert K Kojima W Lesslauer W Rinner H Lassmann H Wekerle 1997 TNFa receptor fusion protein prevents experimental autoimmune encephalomyelitis and demyelination in Lewis rats: an overview J Neuroimmunol 72 163 168 10.1016/S0165-5728(96)00183-X 9042109 (Pubitemid 27062772)
68. N Mohan ET Edwards TR Cupps PJ Oliverio G Sandberg H Crayton, et al. 2001 Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides Arthritis Rheum 44 12 2862 2869 10.1002/1529- 0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W 11762947 (Pubitemid 34016206)
69. IS Shin AN Baer HJ Kwon EJ Papadopoulos JN Siegel 2006 Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy Arthritis Rheum 54 5 1429 1434 10.1002/art.21814 16645971
70. I Simsek H Erdem S Pay G Sobaci A Dinc 2007 Optic neuritis occurring with anti-tumour necrosis factor alpha therapy Ann Rheum Dis 66 9 1255 1258 10.1136/ard.2006.066787 17456525 (Pubitemid 47309747)
71. CW Lees AI Ali AI Thompson GT Ho RO Forsythe L Marquez, et al. 2009 The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up Aliment Pharmacol Ther 29 3 286 297 10.1111/j.1365-2036.2008.03882.x 19132970
72. Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis published online 23 Jul 2009; doi: 10.1136/ard.2009.111500
73. P Lozeron C Denier C Lacroix D Adams 2009 Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy Arch Neurol 66 4 490 497 10.1001/archneurol.2009.11 19364934
74. NL Sicotte RR Voskuhl 2001 Onset of multiple sclerosis associated with anti-TNF therapy Neurology 57 10 1885 1888 11723281
75. E Muteis-Olivas C Pérez-García J Roquer-González J Maymo-Guarch 2005 Esclerosis múltiple tras el tratamiento con anticuerpo anti-TNF-α Med Clin (Barc) 125 756 759
76. E Dubcenco CA Ottaway DL Chen JP Baker 2006 Neurological symptoms suggestive of demyelination in Crohn's disease after infliximab therapy Eur J Gastroenterol Hepatol 18 5 565 566 10.1097/00042737-200605000-00021 16607158 (Pubitemid 43832762)
77. PJ Enayati KA Papadakis 2005 Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis J Clin Gastroenterol 39 4 303 306 10.1097/01.mcg.0000155126.82171.32 15758624 (Pubitemid 40393245)
78. C Richez P Blanco A Lagueny T Schaeverbeke J Dehais 2005 Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers Neurology 64 8 1468 1470 15851749
79. P Richette P Dieudé J Damiano F Lioté P Orcel T Bardin 2004 Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis J Rheumatol 31 10 2079 2081 15468380
80. CW Thomas Jr BG Weinshenker WJ Sandborn 2004 Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease Inflamm Bowel Dis 10 1 28 31 10.1097/00054725-200401000-00004 15058523 (Pubitemid 38072442)
81. K Vadikolias G Kouklakis I Heliopoulos P Argyropoulou N Papanas M Tzilonidou, et al. 2007 Acute paraplegia after the initiation of anti-tumour necrosis factor-alpha therapy for Crohn's disease Eur J Gastroenterol Hepatol 19 2 159 162 10.1097/01.meg.0000250589.45984.b4 17273002 (Pubitemid 46204334)
82. HF Cay HA Gungor I Sezer C Kacar N Balci 2006 Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report J Clin Pharm Ther 31 6 645 648 10.1111/j.1365-2710.2006.00779.x 17176371 (Pubitemid 44813778)
83. J Jarand DW Zochodne LO Martin C Voll 2006 Neurological complications of infliximab J Rheumatol 33 5 1018 1020 16511935
84. M Tanno I Nakamura S Kobayashi K Kurihara K Ito 2006 New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients Clin Rheumatol 25 6 929 933 10.1007/s10067-005-0097-x 16328088 (Pubitemid 44473174)
85. A Winkelmann R Patejdl S Wagner R Benecke UK Zettl 2008 Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy J Neurol 255 Suppl 6 109 114 10.1007/s00415-008-6020-z 19300970
86. A Fromont J De Seze MC Fleury JF Maillefert T Moreau 2009 Inflammatory demyelinating events following treatment with anti-tumor necrosis factor Cytokine 45 2 55 57 10.1016/j.cyto.2008.11.002 19109035
87. HJ Freeman B Flak 2005 Demyelination-like syndrome in Crohn's disease after infliximab therapy Can J Gastroenterol 19 5 313 316 15915246
88. DR Hooper MA Tarnopolsky SK Baker 2008 Lewis-Sumner syndrome associated with infliximab therapy in rheumatoid arthritis Muscle Nerve 38 4 1318 1325 10.1002/mus.21051 18671292
89. MG Tektonidou J Serelis FN Skopouli 2007 Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment Clin Rheumatol 26 2 258 260 10.1007/s10067-006-0317-z 16683176 (Pubitemid 46020257)
90. SA Sukal L Nadiminti RD Granstein 2006 Etanercept and demyelinating disease in a patient with psoriasis J Am Acad Dermatol 54 1 160 164 10.1016/j.jaad.2005.05.039 16384777 (Pubitemid 41832480)
91. CN Berthelot SJ George S Hsu 2005 Distal lower extremity paresthesia and foot drop developing during adalimumab therapy J Am Acad Dermatol 53 5 Suppl 1 S260 S262 10.1016/j.jaad.2005.03.062 16227104 (Pubitemid 41443484)
92. D Cocito B Bergamasco A Tavella F Poglio I Paolasso PC Costa, et al. 2005 Multifocal motor neuropathy during treatment with infliximab J Peripher Nerv Syst 10 4 386 387 10.1111/j.1085-9489.2005.00053.x 16279990
93. C Rodriguez-Escalera J Belzunegui L Lopez-Dominguez C Gonzalez M Figueroa 2005 Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy Rheumatology (Oxford) 44 1 132 133 10.1093/rheumatology/keh439 (Pubitemid 40124349)
94. OC Singer B Otto H Steinmetz U Ziemann 2004 Acute neuropathy with multiple conduction blocks after TNF alpha monoclonal antibody therapy Neurology 63 9 1754 15534279
95. SJ Jarrett G Cunnane PG Conaghan SJ Bingham MH Buch MA Quinn, et al. 2003 Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series J Rheumatol 30 10 2287 2291 14528531
96. FDA Arthritis Advisory Committee Briefing Document (2003) Efficacy and safety review: infliximab. FDA
97. MH Schiff GR Burmester JD Kent AL Pangan H Kupper SB Fitzpatrick, et al. 2006 Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis Ann Rheum Dis 65 889 894 10.1136/ard.2005.043166 16439435
98. D Khanna M McMahon DE Furst 2004 Safety of tumour necrosis factor-alpha antagonists Drug Saf 27 5 307 324 10.2165/00002018-200427050-00003 15061685 (Pubitemid 38530461)
99. R Midgard M Grønning T Riise G Kvåle H Nyland 1996 Multiple sclerosis and chronic inflammatory diseases. A case-control study Acta Neurol Scand 93 5 322 328 10.1111/j.1600-0404.1996.tb00004.x 8800342
100. NM Nielsen M Frisch K Rostgaard J Wohlfahrt H Hjalgrim N Koch-Henriksen, et al. 2008 Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark Mult Scler 14 6 823 829 10.1177/1352458508088936 18573841
101. AD Sadovnick H Armstrong GP Rice D Bulman L Hashimoto DW Paty, et al. 1993 A population-based study of multiple sclerosis in twins: update Ann Neurol 33 3 281 285 10.1002/ana.410330309 8498811